US · Healthcare · Biotechnology
EPS came in at -1.26 against a street estimate of -0.86 — a miss of 46.5%.
Analysts rate Axsome Therapeutics Inc a strong buy (19 buy, 0 hold, 0 sell out of 19) with an average price target of $282.32.
| Fund | Stake |
|---|---|
| BlackRock Inc | 7.60% |
| Vanguard Portfolio Management, LLC | 4.00% |
| Vanguard Capital Management, LLC | 3.77% |
| FMR Inc | 3.05% |
| T. Rowe Price Associates, Inc. | 2.56% |
| Amvescap Plc. | 2.52% |
| Geode Capital Management, LLC | 2.26% |
| Wellington Management Company LLP | 2.23% |
| Document | Date |
|---|---|
| Company announcement · Q3 2026 | 2026-07-15 |
| Board / officer change · Q2 2026 | 2026-06-09 |
| Shareholder vote results · Q2 2026 | 2026-06-09 |
| Company announcement · Q2 2026 | 2026-06-03 |
| Quarterly report · Q1 2026 | 2026-05-04 |
| Proxy statement · Q2 2026 | 2026-04-24 |
| Annual report FY2025 | 2026-02-23 |
| Quarterly report · Q3 2025 | 2025-11-03 |
Readable in the app.
| Announcement | Date |
|---|---|
| Acquires exclusive global rights to balipodect for neuropsychiatric treatment Axsome Therapeutics acquired exclusive global rights to balipodect (TAK-063), a novel oral drug candidate from Takeda, for treating schizophrenia and Tourette syndrome. Balipodect is a selec | 2026-04-01 |
| Preliminary Q4 and full year 2025 net product revenue announced Axsome Therapeutics announced strong preliminary 2025 financial results with total net product revenue of $638.5 million, representing 66% year-over-year growth. The company's three commerci | 2026-01-12 |
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Axsome Therapeutics Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.